Cytoskeletal defects in cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 3, 2003, Pages 231-241

  McNally, Elizabeth ^a   Allikian, Michael ^a   Wheeler, Matthew T ^a   Mislow, John M ^a   Heydemann, Ahlke ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cardiomyopathy; Cytoskeleton; Dystroglycan; Dystrophin; Emerin; Extracellular matrix; Lamin; Nuclear membrane; Sarcoglycan; Sarcolemma; Sarcomere; Titin; Z line

Indexed keywords

CAVEOLIN 3; CELL PROTEIN; CONNECTIN; CYTOSKELETON PROTEIN; DYSTROBREVIN; DYSTROGLYCAN; DYSTROPHIN; EMERIN; GLYCOPROTEIN; LAMIN A; MEMBRANE PROTEIN; NITRIC OXIDE SYNTHASE; SARCOGLYCAN; SCLEROPROTEIN; SYNTROPHIN;

CARDIOMYOPATHY; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CELL STRUCTURE; CELLULAR DISTRIBUTION; CYTOSKELETON; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC DISORDER; GENETICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INHERITANCE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN LOCALIZATION; REVIEW; SARCOLEMMA; SARCOMERE; SIGNAL TRANSDUCTION;

EID: 0037348244     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00018-X     Document Type: Review

References (129)

1. Felker G.M., Thompson R.E., Hare J.M., Hruban R.H., Clemetson D.E., Howard D.L., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J M. 342:2000;1077-1084.
2. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R., et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern M. 159:1999;29-34.
3. Rando T.A. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24:2001;1575-1594.
4. Rafael J.A., Brown S.C. Dystrophin and utrophin: genetic analyses of their role in skeletal muscle. Microsc Res Tech. 48:2000;155-166.
5. Klietsch R., Ervasti J.M., Arnol W., Campbell K.P., Jorgensen A.O. Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res. 72:1993;349-360.
6. Iwata Y., Pan Y., Hanada H., Yoshida T., Shigekawa M. Dystrophin-glycoprotein complex purified from hamster cardiac muscle. Comparison of the complexes from cardiac and skeletal muscles of hamster and rabbit. J Mol Cell Cardiol. 28:1996;2501-2509.
7. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., Kunkel L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 50:1987;509-517.
8. Ferlini A., Sewry C., Melis M.A., Mateddu A., Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord. 9:1999;339-346.
9. Perloff J.K. Cardiac involvement in heredofamilial neuromyopathic diseases. Cardiovasc Clin. 4:1972;333-344.
10. D'Orsogna L., O'Shea J.P., Miller G. Cardiomyopathy of Duchenne muscular dystrophy. Pediatr Cardiol. 9:1988;205-213.
11. Hoffman E.P., Brown Jr R.H., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:1987;919-928.
12. Newey S.E., Benson M.A., Ponting C.P., Davies K.E., Blake D.J. Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex. Curr Biol. 10:2000;1295-1298.
13. Crawford G.E., Faulkner J.A., Crosbie R.H., Campbell K.P., Froehner S.C., Chamberlain J.S. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol. 150:2000;1399-1410.
14. Yoshida M., Hama H., Ishikawa-Sakurai M., Imamura M., Mizuno Y., Araishi K., et al. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet. 9:2000;1033-1040.
15. Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., Sweeney H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA. 90:1993;3710-3714.
16. Dellorusso C., Crawford R.W., Chamberlain J.S., Brooks S.V. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injured injury. J Muscle Res Cell Motil. 22:2001;467-475.
17. Danialou G., Comtois A.S., Dudley R., Karpati G., Vincent G., Des Rosiers C., et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 15:2001;1655-1657.
18. Rybakova I.N., Patel J.R., Ervasti J.M. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol. 150:2000;1209-1214.
19. Deconinck A.E., Rafael J.A., Skinner J.A., Brown S.C., Potter A.C., Metzinger L., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 90:1997;717-727.
20. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., Sanes J.R. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell. 90:1997;729-738.
21. Ervasti J.M., Ohlendieck K., Kahl S.D., Gaver M.G., Campbell K.P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 345:1990;315-319.
22. Grady R.M., Grange R.W., Lau K.S., Maimone M.M., Nichol M.C., Stull J.T., et al. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol. 1:1999;215-220.
23. Hack A.A., Cordier L., Shoturma D.I., Lain M.Y., Sweeney H.L., McNally E.M. Muscle degeneration without mechanical injury in sssarcoglycan deficiency. Proc Natl Acad Sci USA. 96:1999;10723-10728.
24. Chockalingam P.S., Cholera R., Oak S.A., Zheng Y., Jarrett H.W., Thomason D.B. Dystrophin-glycoprotein complex and Ras and Rho GTPase signaling are altered in muscle atrophy. Am J Physiol Cell Physiol. 283:2002;C500-511.
25. Durbeej M., Henry M.D., Campbell K.P. Dystroglycan in development and disease. Curr Opin Cell Biol. 10:1998;594-601.
26. Williamson R.A., Henry M.D., Daniels K.J., Hrstka R.F., Lee J.C., Sunada Y., et al. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dagl-null mice. Hum Mol Genet. 6:1997;831-841.
27. Henry M.D., Campbell K.P. A role for dystroglycan in basement membrane assembly. Cell. 95:1998;859-870.
28. Miyagoe-Suzuki Y., Nakagawa M., Takeda S. Merosin and congenital muscular dystrophy. Microsc Res Tech. 48:2000;181-191.
29. Gilhuis H.J., ten Donkelaar H.J., Tanke R.B., Vingerhoets D.M., Zwarts M.J., Verrips A., et al. Nonmuscular involvement in merosin-negative congenital muscular dystrophy. Pediatr Neurol. 26:2002;30-36.
30. Xu H., Wu X.R., Wewer U.M., Engvall E. Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet. 8:1994;297-302.
31. Sunada Y., Bernier S.M., Kozak C.A., Yamada Y., Campbell K.P. Deficiency of merosin in dystrophic dy mice and genetic linkage of laminin M chain gene to dy locus. J Biol Chem. 269:1994;13729-13732.
32. Heydemann A., Wheeler M.T., McNally E.M. Cardiomyopathy in animal models of muscular dystrophy. Curr Opin Cardiol. 16:2001;211-217.
33. Henry M.D., Campbell K.P. Dystroglycan inside and out. Curr Opin Cell Biol. 11:1999;602-607.
34. Cote P.D., Moukhles H., Lindenbaum M., Carbonetto S. Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses. Nat Genet. 23:1999;338-342.
35. Cote P.D., Moukhles H., Carbonetto S. Dystroglycan is not required for localization of dystrophin, syntrophin, and neuronal nitric-oxide synthase at the sarcolemma but regulates integrin alpha 7B expression and caveolin-3 distribution. J Biol Chem. 277:2002;4672-4679.
36. Cohn R., Henry M., Michele D., Barresi R., Saito F., Moore S., et al. Disruption of dagl in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell. 110:2002;639.
37. Albrecht D.E., Froehner S.C. Syntrophins and dystrobrevins: defining the dystrophin scaffold at synapses. Neurosignals. 11:2002;123-129.
38. Ichida F., Tsubata S., Bowles K.R., Haneda N., Uese K., Miyawaki T., et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation. 103:2001;1256-1263.
39. Brenman J.E., Chao D.S., Gee S.H., McGee A.W., Craven S.E., Santillano D.R., et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1syntrophin mediated by PDZ domains. Cell. 84:1996;757-767.
40. Venema V.J., Ju H., Zou R., Venema R.C. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J Biol Chem. 272:1997;28187-28190.
41. Minetti C., Sotgia F., Bruno C., Scartezzini P., Broda P., Bado M., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 18:1998;365-368.
42. Woodman S.E., Park D.S., Cohen A.W., Cheung M.W., Chandra M., Shirani J., et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 277:2002;38988-38997.
43. McNally E.M., de Sa Moreira E., Duggan D.J., Bonnemann C.G., Lisanti M.P., Lidov H.G., et al. Caveolin-3 in muscular dystrophy. Hum Mol Genet. 7:1998;871-877.
44. Straub V., Rafael J.A., Chamberlain J.S., Campbell K.P. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol. 139:1997;375-385.
45. Brenman J.E., Chao D.S., Xia H., Aldape K., Bredt D.S. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 82:1995;743-752.
46. Adams M.E., Mueller H.A., Froehner S.C. In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J Cell Bio1. 155:2001;113-122.
47. Hack A.A., Groh M.E., McNally E.M. Sarcoglycans in muscular dystrophy. Microsc Res Tech. 48:2000;167-180.
48. Wheeler M.T., Zarnegar S., McNally E.M. Zeta-Sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum Mol Genet. 11:2002;2147-2154.
49. Ben Hamida M., Ben Hamida C., Zouari M., Belal S., Hentati F. Limb-girdle muscular dystrophy 2C: clinical aspects. Neuromuscul Disord. 6:1996;493-494.
50. Lim L.E., Duclos F., Broux O., Bourg N., Sunada Y., Allamand V., et al. Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet. 11:1995;257-265.
51. Bonnemann C.G., Modi R., Noguchi S., Mizuno Y., Yoshida M., Gussoni E., et al. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex [published erratum appears in Nat Genet 1996 Jan;12(1):110]. Nat Genet. 11:1995;266-273.
52. Noguchi S., McNally E.M., Ben Othmane K., Hagiwara Y., Mizuno Y., Yoshida M., et al. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science. 270:1995;819-822.
53. Nigro V., de Sa Moreira E., Piluso G., Vainzof M., Belsito A., Politano L., et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet. 14:1996;195-198.
54. Straub V., Duclos F., Venzke D.P., Lee J.C., Cutshall S., Leveille C.J., et al. Molecular pathogenesis of muscle degeneration in the delta-sarcoglycan-deficient hamster. Am J Pathol. 153:1998;1623-1630.
55. Allamand V., Campbell K.P. Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum Mol Genet. 9:2000;2459-2467.
56. Tsubata S., Bowles K.R., Vatta M., Zintz C., Titus J., Muhonen L., et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest. 106:2000;655-662.
57. Liu L.A., Engvall E. Sarcoglycan isoforms in skeletal muscle. J Biol Chem. 274:1999;38171-38176.
58. Factor S.M., Minase T., Cho S., Dominitz R., Sonnenblick E.H. Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis. Circulation. 66:1982;342-354.
59. Sakamoto A., Ono K., Abe M., Jasmin G., Eki T., Murakami Y., et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA. 94:1997;13873-13878.
60. Factor S.M., Cho S.H., Scheuer J., Sonnenblick E.H., Malhotra A. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. J Am Coil Cardiol. 12:1988;1599-1604.
61. Sonnenblick E.H., Fein F., Capasso J.M., Factor S.M. Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. B-84B. Am J Cardiol. 55:1985;179.
62. Coral-Vazquez R., Cohn R.D., Moore S.A., Hill J.A., Weiss R.M., Davisson R.L., et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 98:1999;465-474.
63. Cohn R.D., Durbeej M., Moore S.A., Corai-Vazquez R., Prouty S., Campbell K.P. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest. 107:2001;R1-7.
64. Wheeler MT, Korcarz C, Collins K, Lang RL, McNally EM. Reduction of secondary vasospasm limits cardiomyopathy progression (in preparation).
65. Badorff C., Lee G.H., Lamphear B.J., Martone M.E., Campbell K.P., Rhoads R.E., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat M. 5:1999;320-326.
66. Badorff C., Berkely N., Mehrotra S., Talhouk J.W., Rhoads R.E., Knowlton K.U. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J Biol Chem. 275:2000;11191-11197.
67. Xiong D., Lee G.H., Badorff C., Dorner A., Lee S., Wolf P., et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat M. 8:2002;872-877.
68. Vatta M., Stetson S.J., Perez-Verdia A., Entman M.L., Noon G.P., Torre-Amione G., et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet. 359:2002;936-941.
69. Kobayashi K., Nakahori Y., Miyake M., Matsumura K., Kondo-Iida E., Nomura Y., et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature. 394:1998;388-392.
70. Aravind L., Koonin E.V. The fukutin protein family-predicted enzymes modifying cell-surface molecules. Curr Biol. 9:1999;R836-837.
71. Holzfeind P.J., Grewal P.K., Reitsamer H.A., Kechvar J., Lassmann H., Hoeger H., et al. Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle - eye-brain disorders. Hum Mol Genet. 11:2002;2673-2687.
72. Beltran-Valero De Bernabe D., Currier S., Steinbrecher A., Celli J., Van Beusekom E., Van Der Zwaag B., et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet. 71:(5):2002.
73. Brockington M., Blake D.J., Brown S.C., Muntoni F. The gene for a novel glycosyltransferase is mutated in congenital muscular dystrophy MDC1C and limb girdle muscular dystrophy 21. Neuromuscul Disord. 12:2002;233-234.
74. Brockington M., Yuva Y., Prandini P., Brown S.C., Torelli S., Benson M.A., et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 21 as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet. 10:2001;2851-2859.
75. Grewal P.K., Holzfeind P.J., Bittner R.E., Hewitt J.E. Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat Genet. 28:2001;151-154.
76. Michele D.E., Barresi R., Kanagawa M., Saito F., Cohn R.D., Satz J.S., et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature. 418:2002;417-422.
77. Nguyen H.H., Jayasinha V., Xia B., Hoyte K., Martin P.T. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA. 99:2002;5616-5621.
78. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 104:2001;557-567.
79. Bonne G., Carrier L., Richard P., Hainque B., Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res. 83:1998;580-593.
80. Cuda G., Fananapazir L., Epstein N.D., Sellers J.R. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil. 18:1997;275-283.
81. 2+ regulation of thin filament motility. Biochem Biophys Res Commun. 236:1997;760-764.
82. Charron P., Dubourg O., Desnos M., Bennaceur M., Carrier L., Camproux A.C., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 97:1998;2230-2236.
83. Maron B.J., Niimura H., Casey S.A., Soper M.K., Wright G.B., Seidman J.G., et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coil Cardiol. 38:2001;315-321.
84. McConnell B.K., Fatkin D., Semsarian C., Jones K.A., Georgakopoulos D., Maguire C.T., et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res. 88:2001;383-389.
85. Kamisago M., Sharma S.D., DePalma S.R., Solomon S., Sharma P., McDonough B., et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J M. 343:2000;1688-1696.
86. Olson T.M., Michels V.V., Thibodeau S.N., Tai Y.S., Keating M.T. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science. 280:1998;750-752.
87. Semsarian C., Healey M.J., Fatkin D., Giewat M., Duffy C., Seidman C.E., et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 33:2001;2055-2060.
88. Suzuki M., Carlson K.M., Marchuk D.A., Rockman H.A. Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. Circulation. 105:2002;1824-1829.
89. Minamisawa S., Hoshijima M., Chu G., Ward C.A., Frank K., Gu Y., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 99:1999;313-322.
90. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J M. 347:2002;1135-1142.
91. Hein S., Schaper J. Weakness of a giant: mutations of the sarcomeric protein titin. Trends. Mol M. 8:2002;311-313.
92. Li H., Linke W.A., Oberhauser A.F., Carrion-Vazquez M., Kerkviiet J.G., Lu H., et al. Reverse engineering of the giant muscle protein titin. Nature. 418:2002;998-1002.
93. Neagoe C., Kulke M., del Monte F., Gwathmey J.K., de Tombe P.P., Hajjar R.J., et al. Titin isoform switch in ischemic human heart disease. Circulation. 106:2002;1333-1341.
94. Wu Y., Bell S.P., Trombitas K., Witt C.C., Labeit S., LeWinter M.M., et al. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation. 106:2002;1384-1389.
95. Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., Sasse-Klaassen S., et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet. 30:2002;201-204.
96. Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun. 291:2002;385-393.
97. Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., De Seze J., et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet. 71:2002;492-500.
98. Jia Z., Petrounevitch V., Wong A., Moldoveanu T., Davies P.L., Elce J.S., et al. Mutations in calpain 3 associated with limb girdle muscular dystrophy: analysis by molecular modeling and by mutation in m-calpain. Biophys J. 80:2001;2590-2596.
99. Garvey S.M., Rajan C., Lerner A.P., Frankel W.N., Cox G.A. The muscular dystrophy with myositis (mdm) mouse mutation disrupts a skeletal muscle-specific domain of titin. Genomics. 79:2002;146-149.
100. Olson T.M., Illenberger S., Kishimoto N.Y., Huttelmaier S., Keating M.T., Jockusch B.M. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation. 105:2002;431-437.
101. Arber S., Hunter J.J., Ross Jr J., Hongo M., Sansig G., Borg J., et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 88:1997;393-403.
102. Omens J.H., Usyk T.P., Li Z., McCulloch A.D. Muscle LIM protein deficiency leads to alterations in passive ventricular mechanics. Am J Physiol Heart Circ Physiol. 282:2002;H680-H687.
103. Dalakas M.C., Park K.Y., Semino-Mora C., Lee H.S., Sivakumar K., Goldfarb L.G. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J M. 342:2000;770-780.
104. Vicart P., Caron A., Guicheney P., Li Z., Prevost M.C., Faure A., et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet. 20:1998;92-95.
105. Carlsson L., Thornell L.E. Desmin-related myopathies in mice and man. Acta Physiol Scand. 171:2001;341-348.
106. Protonotarios N.I., Tsatsopoulou A.A., Gatzoulis K.A. Arrhythmogenic right ventricular cardiomyopathy caused by a deletion in plakoglobin (Naxos disease). Card Electrophysiol Rev. 6:2002;72-80.
107. Norgett E.E., Hatsell S.J., Carvajal-Huerta L., Cabezas J.C., Common J., Purkis P.E., et al. Recessive mutation in desmopiakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet. 9:2000;2761-2766.
108. Rampazzo A., Nava A., Malacrida S., Beffagna G., Bauce B., Rossi V., et al. Mutation in human desmoplakin domain binding to plakogiobin causes a dominant form of arrhythmogenic right ventdcular cardiomyopathy. Am J Hum Genet. 71:2002;1200-1206.
109. McKoy G., Protonotarios N., Crosby A., Tsatsopoulou A., Anastasakis A., Coonar A., et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease. Lancet. 355:2000;2119-2124.
110. Hijikata T., Murakami T., Imamura M., Fujimaki N., Ishikawa H. Plectin is a linker of intermediate filaments to Z-discs in skeletal muscle fibers. J Cell Sci. 112:1999;867-876.
111. Smith F.J., Eady R.A., Leigh I.M., McMillan J.R., Rugg E.L., Kelsell D.P., et al. Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet. 13:1996;450-457.
112. Towbin J.A., Bowles N.E. The failing heart. Nature. 415:2002;227-233.
113. Semsarian C., Ahmad I., Giewat M., Georgakopoulos D., Schmitt J.P., McConnell B.K., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 109:2002;1013-1020.
114. Pyle W.G., Sumandea M.P., Solaro R.J., De Tombe P.P. Troponin I serines 43/45 and regulation of cardiac myofilament function. Am J Physiol Heart Circ Physiol. 283:2002;H1215-H1224.
115. Wilson K.L. The nuclear envelope, muscular dystrophy and gene expression. Trends Cell Biol. 10:2000;125-129.
116. Holmer L., Worman H.J. Inner nuclear membrane proteins: functions and targeting. Cell Mol Life Sci. 58:2001;1741-1747.
117. Burke B., Stewart C.L. Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol. 3:2002;575-585.
118. Goldman R.D., Gruenbaum Y., Moir R.D., Shumaker D.K., Spann T.P. Nuclear lamins: building blocks of nuclear architecture. Genes Dev. 16:2002;533-547.
119. Fatkin D., MacRae C., Sasaki T., Wolff M.R., Porcu M., Frenneaux M., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J M. 341:1999;1715-1724.
120. Bonne G., Di Barletta M.R., Varnous S., Becane H.M., Hammouda E.H., Merlini L., Muntoni F., Greenberg C.R., Gary F., Urtizberea J.A., Duboc D., Fardeau M., Toniolo D., Schwartz K. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 21:1999;285-288.
121. Lin F., Worman H.J. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem. 268:1993;16321-16326.
122. Helbling-Leclerc A., Bonne G., Schwartz K. Emery-Dreifuss muscular dystrophy. Eur J Hum Genet. 10:2002;157-161.
123. Haraguchi T., Koujin T., Segura-Totten M., Lee K.K., Matsuoka Y., Yoneda Y., et al. BAF is required for emerin assembly into the reforming nuclear envelope. J Cell Sci. 114:2001;4575-4585.
124. Lee K.K., Haraguchi T., Lee R.S., Koujin T., Hiraoka Y., Wilson K.L. Distinct functional domains in emerin bind lamin A and DNA-bridging protein BAF. J Cell Sci. 114:2001;4567-4573.
125. Ostlund C., Bonne G., Schwartz K., Worman H.J. Properties of lamin A mutants found in Emery-Dreifuss muscular dystrophy, cardiomyopathy and Dunnigan-type partial lipodystrophy. J Cell Sci. 114:2001;4435-4445.
126. Cao H., Hegele R.A. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 9:2000;109-112.
127. Shackleton S., Lloyd D.J., Jackson S.N., Evans R., Niermeijer M.F., Singh B.M., et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet. 24:2000;153-156.
128. Lloyd D.J., Trembath R.C., Shackleton S. A novel interaction between lamin A and SREBPI: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet. 11:2002;769-777.
129. Mislow J.M., Holaska J.M., Lee K.K., Segura-Totten M., Wilson K.L., McNally E.M. Nesprin-1alpha self-associates and binds directly to emerin and lamin A in vitro. FEBS Lett. 525:2002;135-140.